Jesus Hernandez, MD
Rheumatology · Sugar Land, TXNPI 1437183910
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $136,901 of the $186,152 with a category attached, or 73.5%. 38 manufacturers reported payments, led by Lilly USA, LLC at 28.5% of the total. Reporting peaked in 2019 at $79,672 and has fallen 91.4% since, to $6,839 in 2025. Among rheumatology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,430 payments — averaging $130.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$53K
- AbbVie$51K
- Amgen$26K
- Bristol Myers Squibb$21K
- AstraZeneca$14K
- Johnson & Johnson$6K
- plus $16K from 32 others
Across 26 payments — averaging $6815.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$163K
- Genentech, Inc.$9K
- Amgen$5K
What the payments were for
- Consulting fees$12,5537%
- Speaking & faculty fees$136,90174%
- Travel & lodging$9,1365%
- Food & beverage$27,12615%
- Education$4360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 106 | $53,024 |
| AbbVie | 243 | $51,257 |
| Amgen(2 entities) | 251 | $26,074 |
| Bristol Myers Squibb | 43 | $20,682 |
| AstraZeneca(2 entities) | 101 | $13,662 |
| Johnson & Johnson(2 entities) | 89 | $5,744 |
| Mallinckrodt Hospital Products Inc. | 14 | $4,642 |
| UCB, Inc. | 106 | $2,619 |
| Pfizer | 119 | $1,641 |
| Novartis | 53 | $1,393 |
| E.r. Squibb & Sons, L.L.C. | 119 | $1,361 |
| Sanofi | 29 | $732 |
| GSK | 39 | $709 |
| Genentech USA, Inc. | 24 | $552 |
| Organon | 26 | $380 |
| Octapharma USA, Inc. | 3 | $310 |
| Aurinia Pharma U.S., Inc. | 11 | $208 |
| Mallinckrodt Enterprises LLC | 14 | $204 |
| Invivyd Inc | 6 | $145 |
| Boehringer Ingelheim | 5 | $111 |
| Sobi, Inc | 4 | $108 |
| Zyla Life Sciences, Inc. | 3 | $101 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Radius Health, Inc. | 4 | $65 |
| Kyowa Kirin, Inc. | 2 | $53 |
| Bioventus LLC | 2 | $32 |
| GRT US Holding, Inc. | 1 | $29 |
| Medtronic | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Cumberland Pharmaceuticals, Inc. | 2 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Hospira, Inc. | 1 | $22 |
| Mylan Institutional Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Biocon Biologics Inc | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Gilead | 1 | $13 |
| Medexus Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$186,152 in reported general payments places this provider in the 95th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 32 | $254,777 |
| Enbrel SureclickEtanercept | 19 | $232,940 |
| RinvoqUpadacitinib | 27 | $183,252 |
| Orencia ClickjectAbatacept | 25 | $155,425 |
| TremfyaGuselkumab | 11 | $146,995 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 12 | $121,716 |
| OtezlaApremilast | 24 | $118,459 |
| SaphneloAnifrolumab-Fnia | 12 | $63,227 |
| Hydroxychloroquine Sulfate | 354 | $11,634 |
| MethotrexateMethotrexate Sodium | 114 | $2,681 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 86 | $2,553 |
| Mycophenolate Mofetil | 32 | $2,208 |
| Cevimeline Hcl | 11 | $2,002 |
| Celecoxib | 52 | $1,419 |
| Sulfasalazine | 36 | $1,334 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $51,257 | $183,25227 claims |
| Johnson & JohnsonTremfya | $5,744 | $146,99511 claims |
| AmgenOtezla | $26,074 | $118,45924 claims |
| AstraZenecaSaphnelo | $13,662 | $63,22712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 512 rheumatology providers in Texas.
Other rheumatology in Sugar Land
- Namieta JanssenSugar Land$375K
- Susan MathewSugar Land$56K
- John CushDallas$3.7M
- Sanjay ChabraEl Paso$3.3M
- Dhiman BasuColleyville$1.8M
- Frank WellborneNew Braunfels$1.4M
- Christopher ParkerWest Lake Hills$1.4M
- Pendleton WickershamSan Antonio$954K
- Henry TownsendPlano$738K
- Zoran KurepaDallas$483K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.